Will Momenta report 1st Q 2012 earnings results tomorrow May 3, 2012, before market open? 1st Q 2012 revenues are expected to be $37.38 million compared to $78.17 million for the same quarter last year. Earnings per share for the first quarter are expected to be 21 cents a share from $1.13 a share last year. I assume that this will not affect share price but a decision on Copaxone will. Can anybody judicially predict when is this expected? A few days ago TEVA reported interim data from a study, which suggests that MS patients who switched to Copaxone from interferon-beta treatment showed a significant reduction in spasticity. http://www.globes.co.il/serveen/globes/docview.asp?did=1000744232&fid=1725 Will wait and see.